|
|
| Research article summary (published 30 Aug 2003): |
Bayesian approaches to joint cure-rate and longitudinal models with applications to cancer vaccine trials.
Full Abstract
Complex issues arise when investigating the association between longitudinal immunologic measures and time to an event, such as time to relapse, in cancer vaccine trials. Unlike many clinical trials, we may encounter patients who are cured and no longer susceptible to the time-to-event endpoint. If there are cured patients in the population, there is a plateau in the survival function, S(t), after sufficient follow-up. If we want to determine the association between the longitudinal measure and the time-to-event in the presence of cure, existing methods for jointly modeling longitudinal and survival data would be inappropriate, since they do not account for the plateau in the survival function. The nature of the longitudinal data in cancer vaccine trials is also unique, as many patients may not exhibit an immune response to vaccination at varying time points throughout the trial. We present a new joint model for longitudinal and survival data that accounts both for the possibility that a subject is cured and for the unique nature of the longitudinal data. An example is presented from a cancer vaccine clinical trial.
Author information
Author/s: Brown, Elizabeth R (ER); Ibrahim, Joseph G (JG);
Affiliation: Department of Biostatistics, University of Washington, Seattle, Washington 98105, USA. elizab(-atsign-)u.washington.edu
Journal and publication information
Publication Type: Journal Article
Journal: Biometrics (Biometrics), published in United States. (Language: eng)
Reference: 2003-Sep; vol 59 (issue 3) : pp 686-93
Dates: Created 2003/11/06; Completed 2004/05/27; Revised 2007/11/15;
PMID: 14601770, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Technology evaluation: ISIS-3521.
30 May 1999 - Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice.
29 Sep 2006 - Telomerase and its potential for therapeutic intervention.
30 Jun 2007 - Oncolytic virotherapy as a personalized cancer vaccine.
30 Jul 2008 - Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.
30 Dec 1996 - Immune monitoring of cancer vaccines. Report on a workshop held at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy.
30 Aug 1996 - Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
18 Jan 1999 - CpG oligonucleotides as immune adjuvants.
30 Dec 1999 - Viral vectors for gene transfer into antigen presenting cells.
29 Sep 1999
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.